A carregar...
Pimavanserin: A novel therapeutic option for Parkinson disease psychosis
PURPOSE OF REVIEW: In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. RECENT F...
Na minha lista:
| Publicado no: | Neurol Clin Pract |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669409/ https://ncbi.nlm.nih.gov/pubmed/29185542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000342 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|